

REMARKS

As stated in the amendment filed March 2, 2007, this supplemental amendment includes additional evidence of unexpected results as follows:

- a) a Declaration filed under Rule 132 regarding the results from a clinical study by Jean-Marie DUPUY. A Phase II study demonstrates the safety and efficacy of the combined treatment of chemotherapy and administration of macrophage cells in ovarian cancer patients.
- b) a note from Dr. C. LOUVET (in French and English translation) that identifies the patients (i.e., patient codes NESM, ROBC, NABR and TYMN) that participated in the study on activated macrophages and chemotherapy.

The Examiner is asked to contact the undersigned should there be any questions regarding the declaration or note.

In view of the present amendment and amendment of March 2, 2007, it is believed that the present application is in condition for allowance.

The Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any

overpayment to Deposit Account No. 25-0120 for any additional
fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17.

Respectfully submitted,

YOUNG & THOMPSON



Robert Madsen, Reg. No. 58,543
745 South 23rd Street
Arlington, VA 22202
Telephone (703) 521-2297

RAM/fb

APPENDIX:

- Declaration Under Rule 132 of Jean-Marie DUPUY
- Note of Dr. Christophe LOUVET